Novartis AG and Molecular Partners AG on Monday reported positive topline data from their antiviral Covid-19 treatment ensovibep, and will seek expedited regulatory authorizations globally.

The results from a Phase 2 study of 407 patients receiving a single intravenous dose of ensovibep showed a 78% reduction in hospitalization or emergency-room visits related to Covid-19 compared with a placebo, and a improvement in time to a clinical recovery, Novartis said.

The ensovibep treatment continues to maintain protection against variants of concern identified so far, including Omicron, the Basel-based drugmaker said.

Novartis NVS, +1.16% NOVN, +0.75% also said it will exercise its option and pay 150 million Swiss francs ($163.3 million) to in-license ensovibep from Molecular Partners MOLN, -3.39% MOLN, +27.37% and accelerate manufacturing scale-up.

It also plans to seek expedited regulatory authorizations globally, first via the U.S. Food and Drug Administration’s emergency-use authorization.

If approved, ensovibep will be the first multispecific antiviral molecule for the treatment of Covid-19, Novartis said.

Write to Ed Frankl at [email protected]

Source: This post first appeared on http://marketwatch.com/

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

NewsWatch: Here’s what stock-market experts are blaming Friday’s wild price swings—and it’s not just quadruple witching

Barron’s LVMH: Ascendant or Peaking? Readers weigh in on LVMH, Ray Dalio’s…

More Schools Defying State Governments To Impose Mask Mandates — Here’s What Could Happen Next

Topline State-level bans that prohibit school districts from imposing their own mask…

The Fed: Fed accelerates taper of bond purchases, eyes three interest-rate hikes in 2022

The Federal Reserve on Wednesday said it will phase out its bond-buying…